Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from ABBV

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 39 strange trades.

Benzinga

AbbVie Whale Trades Spotted

Someone with a lot of money to spend has taken a bearish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

3 Dividend Growth Stocks to Buy During This Market Correction

One characteristic of a high-quality stock is a consistent track record of hiking dividends. This indicates a strong business that can thrive in all types of economic conditions, and a management team focused on returning capital to shareholders. Here are 3 such ‘dividend growth’ stocks that investors should consider: Microsoft…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Looking At AbbVie's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 48 strange trades.

Benzinga

FDA Clears AbbVie's Rinvoq For Moderate To Severe Active Ulcerative Colitis

The FDA approved AbbVie Inc's (NYSE:ABBV) Rinvoq (upadacitinib) for adults patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to tumor necrosis factor (TNF) blockers. This FDA approval is the first indication for Rinvoq in gastroenterology and is supported by efficacy and safety data from…

Benzinga

This Is What Whales Are Betting On AbbVie

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 16 strange trades.

Benzinga

AbbVie, Gedeon Richter Join Forces To Develop Dopamine Receptor Modulators For Neuropsychiatric Diseases

AbbVie Inc (NYSE: ABBV) and Gedeon Richter Plc have

Benzinga

Read news from The Economist, FT, and more,
with one subscription

AbbVie's Migraine Treatment Drug Touts Encouraging Data In Preventive Treatment Setting

AbbVie Inc (NYSE: ABBV) has reported data from the Phase 3 PROGRESS trial of atogepant (Qulipta) for the

Benzinga

AbbVie, Alvotech Resolve US Patent Dispute Related To Humira Biosimilar

Alvotech Holdings S.A. has

Benzinga

The Daily Biotech Pulse: Pfizer Begins Late-Stage Pediatric COVID Pill Study, Midatech And J&J Unit Expand R&D Collaboration, AbbVie-Alvotech Settle Humira Dispute

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 5.52% on an annualized basis.

Benzinga

Looking At AbbVie's Recent Whale Trades

Benzinga

AbbVie Files Imbruvica US Application For Pediatric Patients with Chronic Graft Versus Host Disease

AbbVie Inc (NYSE: ABBV) has

Benzinga

Where AbbVie Stands With Analysts

Over the past 3 months, 9 analysts have published their opinion on AbbVie (NYSE:ABBV) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

What Are Whales Doing With AbbVie

StockNews.com

3 Unstoppable Healthcare Stocks to Buy and Hold in 2022

The healthcare industry has ridden a promising wave of innovation and investments over the past few years. Also, with continuing acceleration in the digital transformation of healthcare and breakthrough developments, with healthcare expenditure expected to grow in the coming years, the industry’s prospects look bright. Therefore, we think healthcare stocks…

Benzinga

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 5.85% on an annualized basis.

StockNews.com

Forget AstraZeneca, Buy These 4 Pharmaceutical Stocks Instead

Despite the rising demand for COVID-19 vaccines and other pharmaceutical products, AstraZeneca (AZN) has failed to deliver impressive earnings in its last quarter. While its recent drug launches are expected to do well in the long run, the consensus earnings estimate for the company in the current quarter indicates tepid…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Check Out What Whales Are Doing With ABBV

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 22 strange trades.

StockNews.com

3 Warren Buffett Stocks to Buy in February: DaVita, Bristol Myers Squibb, and AbbVie

Warren Buffett’s value investing strategy has paid off, as its investment firm Berkshire Hathaway (BRK.A) has outperformed the broader market. Recently, the billionaire has become worther than Meta Platforms (FB) founder Mark Zuckerberg. Hence, we believe that the Berkshire Hathaway holdings AbbVie (ABBV), Bristol-Myers Squibb (BMY), and DaVita (DVA) might…

Benzinga

AbbVie Expects Solid FY22 As Botox, Skyrizi Power Q4 Earnings

AbbVie Inc (NYSE: ABBV) reports

Benzinga

AbbVie: Q4 Earnings Insights

AbbVie (NYSE:ABBV) reported its Q4 earnings results on Wednesday, February 2, 2022 at 07:44 AM. Here's what investors need to know about the announcement.

Benzinga

Earnings Outlook For AbbVie

AbbVie (NYSE:ABBV) is set to give its latest quarterly earnings report on Wednesday, 2022-02-02. Here's what investors need to know before the announcement. Analysts estimate that AbbVie will likely report an Earnings Per Share (EPS) of $3.28.

Benzinga

AbbVie Whale Trades For January 25

Someone with a lot of money to spend has taken a bullish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Analyst Ratings For AbbVie

Within the last quarter, AbbVie (NYSE:ABBV) has observed the following analyst ratings:

1 … 7 8 9 10

People

Jaimini DesaiJaimini Desai

59 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Places

United States

265,292 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.